Rat dog micro-cap picks... Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks...

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Condor who wrote (16952)	1/8/2004 9:33:48 AM
From: Bucky Katt	Read Replies (1) of 48461

T/a indicates real buyers. If they get a DOD-DARPA contract for development of one of their bio-tests the thing will take off like we expect. So, I guess the keyword with the bio-turd is expect the un-expected... The Company's goal is to become the leader in the development of rapid, easy to use, cost effective nucleic acid-based technology products. Our technology is applicable to nearly any nucleic acid testing situation, and thus offers an extremely broad range of potential commercial and research applications. The Company is focused on directly participating in the following industry segments for nucleic acid testing: Extraction/Sample Preparation - Total annual sales of reagents for the preparation and purification of nucleic acids in 2001 was estimated to be $760 million, and is expected to grow to over $1.3 billion annually by the year 2005. Clinical Diagnostics - The total annual sales of all clinical diagnostic applications was estimated to be in excess of $21 billion in 2001. Of this total, nucleic acid based diagnostics represented approximately 7% or $1.5 billion. It is anticipated that the total clinical diagnostics industry will grow to over $35 billion by the year 2005. The nucleic acid segment is expected to grow at a much more rapid rate as new technologies enable new testing and cannibalize old testing methodologies. >>Biological Warfare Agent Detection - The current and future size of this market are unknown at this time, but clearly this is an area of anticipated growth in the area of nucleic acid diagnostics. For all other industries/applications for the Company's products/technologies, including but not limited to: food pathogen detection, water pathogen detection, veterinary diagnostics, and forensics, the Company plans to adopt a licensing strategy. xtrana.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next